Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Biohaven Ltd.NYSE: BHVN
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares growth accelerates
Q2 FY2026 weighted avg shares of 150.64M shares rose 47.1% year over year, ahead of the +31.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +34.0% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +47.1% holds above the trailing-twelve-month pace of +31.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 107.62M USD
- Year-over-year change
- +18.0%
- 4-year CAGR
- +31.7%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 107.62M | +18.0% |
| FY2024 | 2024-12-31 | 91.23M | +28.1% |
| FY2023 | 2023-12-31 | 71.2M | +59.1% |
| FY2022 | 2022-12-31 | 44.74M | +24.9% |
| FY2021 | 2021-12-31 | 35.82M | — |
Weighted Avg Shares vs competitors
How BHVN compares with its peers on the latest reported figures
- BHVN's LTM Jun 2026 weighted avg shares of 131.06M shares is the 3rd highest of the 11 companies compared; the peer median is 70.1M shares.
- Its year-over-year change of +31.1% is the 2nd highest of 11, against a peer median of +10.6%.
- Over three fiscal years its annual growth of +34.0% compares with a peer median of +8.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 306.35M | +3.0% | +1.6% | |
| LTM Mar 2026 | 167.52M | +11.9% | +5.8% | |
| LTM Jun 2026 | 131.06M | +31.1% | +34.0% | |
| LTM Mar 2026 | 110.2M | +9.3% | +12.1% | |
| LTM Sep 2026 | 106.83M | +34.8% | +93.1% | |
| LTM Sep 2026 | 72.36M | +9.0% | +12.4% | |
| LTM Jun 2026 | 67.85M | +14.4% | +34.2% | |
| LTM Sep 2026 | 65.72M | +16.6% | +20.8% | |
| LTM Mar 2026 | 50.45M | +0.8% | +3.3% | |
| LTM Mar 2026 | 46.54M | +13.7% | +5.3% | |
| LTM Mar 2026 | 43.37M | -1.7% | -3.2% | |
| Peer median (excluding BHVN) | 70.1M | +10.6% | +8.9% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.14M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.14M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Selling, General & Admin | 37.41M | 130.86M | 62.77M | 89.24M | 106.17M |
| Operating Expenses | 218.9M | 567.93M | 436.05M | 885.11M | 741.24M |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| EBITDA | (211.04M) | (568.46M) | (402.64M) | (837.83M) | (727.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (218.9M) | (567.93M) | (436.05M) | (885.11M) | (745.38M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 17.73M | 21.33M | 14.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.47M | (1.91M) | 26.5M | 39.42M | 8M |
| Income Before Tax | (212.43M) | (569.84M) | (409.55M) | (845.69M) | (737.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.37M | 438K | (1.38M) | 735K | 1.44M |
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| EPS (Diluted) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| Weighted Avg Shares | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
| Weighted Avg Shares (Diluted) | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.